Skip to main content
Clinical Trials/JPRN-UMIN000026277
JPRN-UMIN000026277
Not yet recruiting
未知

Clinical trial to investigate the efficacy and safety of fish skin-derived collagen on wall thickness in the carotid artery and clinical symptom, etc. in healthy adults and subjects with mild carotid artery hypertrophy by a double-blind parallel group comparison design - Clinical trial to investigate the efficacy and safety of fish skin-derived collagen on wall thickness in the carotid artery and clinical symptom, etc. in healthy adults and subjects with mild carotid artery hypertrophy by a double-blind parallel group comparison design

Kojinkai Medical Corporation Shin-Nihonbashi Ishii clinic0 sites120 target enrollmentFebruary 25, 2017

Overview

Phase
未知
Intervention
Not specified
Conditions
Healthy adults and subjects with mild carotid artery hypertrophy
Sponsor
Kojinkai Medical Corporation Shin-Nihonbashi Ishii clinic
Enrollment
120
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 25, 2017
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Kojinkai Medical Corporation Shin-Nihonbashi Ishii clinic

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • \-Subjects who participated in any clinical trial within 4 months prior to administrating study foods. \-Subjects who had been taking supplements or Foods for Specified Health Uses mainly composed of collagen or placenta within 6 months prior to administrating study foods, and subjects who have ever taken Natural Marin Collagen Jelly (even once). \-Employees and family of implementation medical institution \-Pregnant or nursing women \-Subjects with low potential to comply with the study protocol and subjects who are otherwise judged by the principal investigator or sub\-investigator to be inappropriate for inclusion in the study

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Clinical Trial to investigate the efficacy and safety of ANGOCIN® Anti-Infekt N against placebo preventing urinary tract infections in catheterized patientsProphylaxis of catheter-associated chronically inflammatory recurring urinary tract infections in adult patientsMedDRA version: 20.0Level: LLTClassification code 10046544Term: Urinary infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 21.0Level: LLTClassification code 10007810Term: Catheter related infectionSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]
EUCTR2016-004842-27-DERepha GmbH100
Active, not recruiting
Phase 1
Clinical trial for examination of efficacy and safety of ANGOCIN® Anti-Infekt N versus placebo in the continous prophylaxis of chronically recurring uncomplicated cystitisContinuous prophylaxis of chronically recurring uncomplicated cystitisMedDRA version: 20.1 Level: LLT Classification code 10011786 Term: Cystitis chronic System Organ Class: 100000004862MedDRA version: 21.1 Level: PT Classification code 10063057 Term: Cystitis noninfective System Organ Class: 10038359 - Renal and urinary disordersTherapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]
EUCTR2013-004653-25-DERepha GmbH224
Active, not recruiting
Phase 1
Clinical trial for examination of efficacy and safety of MYRRHINIL-INTEST® versus placebo in patients with diarrhea-dominant irritable bowel syndrom (IBS-D)Confirmed diagnosis of diarrhea-dominant irritable bowel syndrome (IBS-D) by a specialist physician and/or internal medicine and/or general medicineMedDRA version: 26.0Level: LLTClassification code 10060845Term: Diarrhea predominant irritable bowel syndromeSystem Organ Class: 10017947 - Gastrointestinal disordersTherapeutic area: Diseases [C] - Digestive System Diseases [C06]
EUCTR2019-000307-32-DERepha GmbH220
Active, not recruiting
Not Applicable
Clinical study to investigate the efficacy and safety of an estradiol containing cream (0.01 % estradiol) in patients with senile skidermatoporosis stage I and IITherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
EUCTR2011-002464-24-DEDr. August Wolff GmbH & Co. KG Arzneimittel
Completed
Not Applicable
Clinical study to investigate the efficacy and safety of iliac stenting in patients with peripheral arterial diseasePeripheral arterial disease(PAD), Arteriosclerosis obliterans(ASO)
JPRN-UMIN000016264Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan100